ASX ANNOUNCEMENT

3 June 2024

Following EGM vote Opyl announces successful transition of Opin to Trial Screen

Melbourne, Australia – Opyl Limited (ASX:OPL or "the Company") is pleased to announce the successful transition of Opin to Trial Screen, now under the ownership and leadership of Dr. Hugo Stephenson. This milestone reflects Opyl's strategic focus on refining its portfolio and concentrating resources on the further development of TrialKey.

Key Highlights

- **Ownership Transition**: Dr. Hugo Stephenson has taken ownership of Opin, which has been renamed Trial Screen. This change underscores Opyl's commitment to streamlining its operations and focusing on TrialKey.
- **Strategic Investment**: As part of the agreement, Dr. Stephenson will invest approximately $1.2 million into Trial Screen over the next 12 months. This investment is aimed at bolstering the business through enhanced travel, US-based sales and marketing initiatives, and software development.
- **Opyl's Stake:** Opyl will continue to hold a 20% share in Trial Screen, maintaining a vested interest in the company's success and growth. The transition will also see significant improvements in Opyl's financial position, enabling a stronger focus on high-growth opportunities within the clinical trial and medical research sectors.

This announcement has been authorised for release by the board.

-ENDS-

For general enquiries:

Email: info@opyl.ai
Website: www.opyl.ai

For investor enquiries:

Bernice Averion
Head of Marketing and Communications
Phone: +61 415 311 957
Email: bernice.averion@opyl.ai

About Opyl Limited (ASX: OPL)

Opyl Limited is an AI company dedicated to leveraging data and technology to transform the landscape of clinical trials and medical research. With a commitment to innovation and strategic growth, Opyl is positioned to lead the way in shaping the future of healthcare solutions.